AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (March 2014)

13 slides from AVEO Pharmaceuticals's investor presentation, Mar 13, 2014

  1. Slide 1: 2014 Strategic Plan

    2014 Strategic Plan 1 MARCH 13, 2014 Exhibit 99.2

  2. Slide 2: Strategy Focused on Value Creation

    Value Creation Internal Resources GDF-15 Platform Tivozanib AV-203 Ficlatuzumab Partnering Additional Opportunistic Strategic Initiatives A Strategy Focused on Value Creation

  3. Slide 3: Clinical Stage Assets Value to be Realized through Partnerships

    Clinical Stage Assets Value to be Realized through Partnerships

  4. Slide 4: Clinical Status Development Plans: AV-203

    March 13, 2014 Clinical Status Development Plans AV-203: ErbB3 Inhibitory Antibody Phase 1 dose-escalation study completed; AV-203 well-tolerated and recommended Phase 2 dose identified CLIA validation completed for patient selection biomarker with response observed in biomarker positive patients Da

  5. Slide 5: Clinical Status Development Plans: Ficlatuzumab

    March 13, 2014 Clinical Status Development Plans Ficlatuzumab: c-Met/HGF Inhibitory Antibody • Phase 2 study of ficlatuzumab in combination with gefitinib vs. gefitinib monotherapy in NSCLC completed in 2012 • Exploratory analysis identified a patient subpopulation deriving benefit from ficlatuzumab

  6. Slide 6: Clinical Status Development Plans: Tivozanib

    March 13, 2014 Clinical Status Development Plans Tivozanib: Triple VEGFR Inhibitory Small Molecule Wind down discontinued trials of tivozanib in RCC, colorectal and triple negative breast cancers 150 patients elected to remain on study (primarily RCC & CRC) Remaining committed costs shared with Aste

  7. Slide 7: AV-380 in Cachexia A Major Opportunity

    AV-380 in Cachexia A Major Opportunity

  8. Slide 8: ~400,000 cancer cachexia patients in major markets

    ~400,000 cancer cachexia patients in 7 major markets 2 What is Cachexia and Who Does it Affect? Cachexia : Complex metabolic syndrome associated with several underlying chronic illnesses and characterized by loss of muscle mass and strength, loss of whole body fat, inflammation, anemia, etc. % preva

  9. Slide 9: GDF-15 – Key Mediator of Cancer Induced Cachexia

    GDF-15 – Key Mediator of Cancer Induced Cachexia • Discovered through AVEO’s Human Response Platform TM – Key tumor signaling pathway identified whose activation triggers a genetic program that results in cachexia – GDF-15 identified as the key mediator – GDF-15 is a soluble factor found in serum/pl

  10. Slide 10: AV-380 – A First-in-Class Opportunity

    AV-380 – A First-in-Class Opportunity • AV-380: Potent humanized GDF-15 inhibitory Mab – Unique mechanism of action that addresses multiple, key underlying mechanisms of cachexia with the potential to • Increase calorie/food intake • Reverse body weight loss • Restore normal body composition • Mecha

  11. Slide 11: Potential Beyond Cancer Cachexia

    17 AV-380 Congestive Heart Failure Cancer Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Cancer Potential Beyond Cancer Cachexia ~5M patients suffering from muscle wasting in the U.S. Initial Focus 1. Morley et al; Am J Clin Nutr 2006;83:735– Additional Cachexia Opportunities Cancer

  12. Slide 12: Additional Opportunistic Strategic Initiatives

    Additional Opportunistic Strategic Initiatives

  13. Slide 13: Summary

    Summary

AVEO Pharmaceuticals — Investor Presentation (March 2014) on 6ix